{"nctId":"NCT02141399","briefTitle":"A Long-Term Safety Study of ALKS 5461","startDateStruct":{"date":"2014-05","type":"ACTUAL"},"conditions":["Major Depressive Disorder"],"count":1485,"armGroups":[{"label":"ALKS 5461","type":"EXPERIMENTAL","interventionNames":["Drug: ALKS 5461"]}],"interventions":[{"name":"ALKS 5461","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Agree to use an approved method of contraception for the duration of the study\n* Have the potential to safely benefit from the administration of ALKS 5461\n* Have a diagnosis of major depressive disorder (MDD)\n* Additional criteria may apply\n\nExclusion Criteria:\n\n* Have a positive test for drugs of abuse\n* Currently pregnant or breastfeeding\n* Have a current primary Axis-I disorder other than MDD\n* Have used opioid agonists (eg, codeine, oxycodone, tramadol, morphine) or opioid antagonists (eg, naloxone, naltrexone) within 14 days\n* Have received electroconvulsive therapy treatment within the last 2 years, or received more than 1 course of electroconvulsive treatment during their lifetime\n* Have attempted suicide within the past 2 years\n* Have a history of intolerance, allergy, or hypersensitivity to buprenorphine or opioid antagonists (eg, naltrexone, naloxone)\n* Have had a significant blood loss or blood donation within the past 60 days\n* Additional criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Adverse Events (AEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1124","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":47,"n":1485},"commonTop":["Nausea","Headache","Constipation","Dizziness","Somnolence"]}}}